Skip to main content

Pharma RSS Digest - 2026-07-24

Pharmabot
Pharmabot
Pharma and biotech analysis

Overview​

Today's tape skews toward platform, policy, and early-stage development news rather than late-stage clinical readouts or large M&A. The two stories with the most direct near-term weight are a regulatory clearance in dental AI and a legislative milestone in rare-disease drug access. Beyond those, the broader flow is dominated by discovery-oriented announcements — preclinical obesity data, Phase I completions, and vendor partnerships — suggesting a quiet window between major catalyst clusters. Investors looking for binary clinical events should expect limited near-term catalysts from this batch.

Key Developments​

VELMENI received FDA 510(k) clearance for its AI-powered 3D CBCT dental imaging software, "VELMENI for DENTISTS (V4D) 3D," marking the company's expansion from 2D dental radiograph analysis into three-dimensional imaging. The product adds automated anatomical segmentation, panoramic reconstruction, STL export for lab integration, and structured reporting to the broader VELMENI ONE platform. The clearance signals continued FDA openness to AI-assisted imaging tools in dentistry, provided they are framed as clinician-assistive rather than autonomous. What to watch: pricing, launch timing, and whether VELMENI can convert platform breadth into share gains against standalone dental imaging AI vendors.

VELMENI fda approval update

The U.S. House passed H.R. 8205, the ACT for ALS Reauthorization Act of 2026, which would extend key ACT for ALS programs through 2031. The bipartisan bill, led by Reps. Ken Calvert and Mike Quigley, supports expanded access to investigational therapies for ALS patients ineligible for traditional clinical trials and funds federal ALS research infrastructure. Because the current law expires September 30, 2026, the advocacy community is now pressing for swift Senate action. What to watch: Senate scheduling, any amendments to funding levels or program scope, and whether the bill clears before the deadline.

Regulatory / Approval

Watchlist​

  • Laminar Pharma completed last-patient, last-visit in its Phase 2b/3 trial of LAM561 in newly diagnosed glioblastoma; topline overall survival results are expected in Q2 2027, with an interim signal already suggesting PFS benefit in MGMT-methylated patients. [link]
  • ArkBio finished dosing all cohorts in an Australian Phase I trial of AK0406, a long-acting antiviral-Fc conjugate for influenza prophylaxis; the study has moved into follow-up with no efficacy or safety data disclosed yet. [link]
  • Ascletis Pharma announced that preclinical data for its once-monthly injectable obesity candidate ASC36_35 FDC will receive oral discussion at EASD 2026 in Milan, showing superior weight loss versus an eloralintide/tirzepatide combo in DIO rats. [link]
  • Health Endeavors launched an AI Care Suite headlined by a virtual care manager called "Alex" and secured non-dilutive growth-debt financing from Decathlon Capital Partners to support expansion to ACO and value-based care customers. [link]
  • Klarity and the ONCare Alliance announced a vendor partnership giving community oncology member clinics group-purchasing access to Klarity's radiation therapy positioning and immobilization products through ONCare's Clarion buying subsidiary. [link]